Biological Therapy in Systemic Lupus Erythematosus

• Main Authors: Mariana Postal, Lilian TL Costallat, Simone Appenzeller
• Format: Article
• Language: English
• Published: Hindawi Limited 2012-01-01
• Series: International Journal of Rheumatology
• Online Access: http://dx.doi.org/10.1155/2012/578641

Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder characterized by multisystem involvement and fluctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life-threatening end-organ manifestations. Despite new and improved therapy having positively impacted the prognosis of SLE, a subgroup of patients do not respond to conventional therapy. Moreover, the risk of fatal outcomes and the damaging side effects of immunosuppressive therapies in SLE call for an improvement in the current therapeutic management. New therapeutic approaches are focused on B-cell targets, T-cell downregulation and costimulatory blockade, cytokine inhibition, and the modulation of complement. Several biological agents have been developed, but this encouraging news is associated with several disappointments in trials and provide a timely moment to reflect on biologic therapy in SLE.